These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 15232365)

  • 1. Racial differences in response rates to consensus interferon in HCV infected patients naive to previous therapy.
    Gaglio PJ; Rodriguez-Torres M; Herring R; Anand B; Box T; Rabinovitz M; Brown RS;
    J Clin Gastroenterol; 2004 Aug; 38(7):599-604. PubMed ID: 15232365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pegylated interferon-alpha-2a plus ribavirin for treatment-naive Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial.
    Liu CH; Liu CJ; Lin CL; Liang CC; Hsu SJ; Yang SS; Hsu CS; Tseng TC; Wang CC; Lai MY; Chen JH; Chen PJ; Chen DS; Kao JH
    Clin Infect Dis; 2008 Nov; 47(10):1260-9. PubMed ID: 18834319
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained virological response rate to pegylated interferon plus ribavirin for chronic hepatitis C in African Americans: results in treatment-naïve patients in a university liver clinic.
    Srivastava S; Bertagnolli M; Lewis JH
    J Natl Med Assoc; 2005 Dec; 97(12):1703-7. PubMed ID: 16396063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.
    Conjeevaram HS; Fried MW; Jeffers LJ; Terrault NA; Wiley-Lucas TE; Afdhal N; Brown RS; Belle SH; Hoofnagle JH; Kleiner DE; Howell CD;
    Gastroenterology; 2006 Aug; 131(2):470-7. PubMed ID: 16890601
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to therapy with pegylated interferon and ribavirin for chronic hepatitis C in hispanics compared to non-Hispanic whites.
    Yu S; Douglass JM; Qualls C; Arora S; Dunkelberg JC
    Am J Gastroenterol; 2009 Jul; 104(7):1686-92. PubMed ID: 19436272
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equally poor outcomes to pegylated interferon-based therapy in African Americans and Hispanics with chronic hepatitis C infection.
    Satapathy SK; Lingisetty CS; Proper S; Chaudhari S; Williams S
    J Clin Gastroenterol; 2010 Feb; 44(2):140-5. PubMed ID: 19826275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection.
    Rodriguez-Torres M; Lawitz E; Yangco B; Jeffers L; Han SH; Thuluvath PJ; Rustgi V; Harrison S; Ghalib R; Vierling JM; Luketic V; Zamor PJ; Ravendhran N; Morgan TR; Pearlman B; O'Brien C; Khallafi H; Pyrsopoulos N; Kong G; McPhee F; Yin PD; Hughes E; Treitel M
    Ann Hepatol; 2016 Nov-Dec 2016; 15(6):834-845. PubMed ID: 27740516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
    Jin R; Cai L; Tan M; McHutchison JG; Dowling TC; Howell CD
    Am J Gastroenterol; 2012 Nov; 107(11):1675-83. PubMed ID: 23090351
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C.
    Rodriguez-Torres M; Jeffers LJ; Sheikh MY; Rossaro L; Ankoma-Sey V; Hamzeh FM; Martin P;
    N Engl J Med; 2009 Jan; 360(3):257-67. PubMed ID: 19144941
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Viral dynamics and response differences in HCV-infected African American and white patients treated with IFN and ribavirin.
    Layden-Almer JE; Ribeiro RM; Wiley T; Perelson AS; Layden TJ
    Hepatology; 2003 Jun; 37(6):1343-50. PubMed ID: 12774013
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients.
    Donlin MJ; Cannon NA; Aurora R; Li J; Wahed AS; Di Bisceglie AM; Tavis JE;
    PLoS One; 2010 Feb; 5(2):e9032. PubMed ID: 20140258
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First Week HCV RNA Level Under the Pegylated Interferon and Ribavirin Treatment Predicts Sustained Virological Response.
    Bayram M; Koksal AR; Alkim H; Boga S; Ergun M; Ozdogan O; Altinkaya E; Alkim C
    Am J Ther; 2016; 23(6):e1612-e1618. PubMed ID: 25933139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.
    Ridruejo E; Solano A; Marciano S; Galdame O; Adrover R; Cocozzella D; Delettieres D; Martínez A; Gadano A; Mandó OG; Silva MO
    Ann Hepatol; 2011; 10(4):452-7. PubMed ID: 21911885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Selective decrease in hepatitis C virus-specific immunity among African Americans and outcome of antiviral therapy.
    Rosen HR; Weston SJ; Im K; Yang H; Burton JR; Erlich H; Klarquist J; Belle SH;
    Hepatology; 2007 Aug; 46(2):350-8. PubMed ID: 17659573
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single-dose infliximab in hepatitis C genotype 1 treatment-naive patients with high serum tumour necrosis factor-alpha does not influence the efficacy of pegylated interferon alpha-2b/ribavirin therapy.
    Cooper C; Shafran S; Greenbloom S; Enns R; Farley J; Hilzenrat N; Williams K; Elkashab M; Abadir N; Neuman M
    Can J Gastroenterol Hepatol; 2014 Jan; 28(1):35-40. PubMed ID: 24212915
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.
    Jacobson IM; Brown RS; McCone J; Black M; Albert C; Dragutsky MS; Siddiqui FA; Hargrave T; Kwo PY; Lambiase L; Galler GW; Araya V; Freilich B; Harvey J; Griffel LH; Brass CA;
    Hepatology; 2007 Oct; 46(4):982-90. PubMed ID: 17894323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C.
    Ishiguro H; Abe H; Seki N; Sugita T; Aida Y; Itagaki M; Sutoh S; Shimada N; Furihata T; Tsubota A; Aizawa Y
    World J Gastroenterol; 2015 Apr; 21(13):3904-11. PubMed ID: 25852275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An IL28B polymorphism determines treatment response of hepatitis C virus genotype 2 or 3 patients who do not achieve a rapid virologic response.
    Mangia A; Thompson AJ; Santoro R; Piazzolla V; Tillmann HL; Patel K; Shianna KV; Mottola L; Petruzzellis D; Bacca D; Carretta V; Minerva N; Goldstein DB; McHutchison JG
    Gastroenterology; 2010 Sep; 139(3):821-7, 827.e1. PubMed ID: 20621700
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Retreatment of hepatitis C with consensus interferon and ribavirin after nonresponse or relapse to pegylated interferon and ribavirin: a national VA clinical practice study.
    Yee HS; Currie SL; Tortorice K; Cozen M; Shen H; Chapman S; Cunningham F; Monto A
    Dig Dis Sci; 2011 Aug; 56(8):2439-48. PubMed ID: 21633833
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.